Front-Line Combo Found Superior for Advanced RCC
Avelumab plus axitinib combination therapy is associated with better outcomes compared with sunitinib alone as first-line treatment of advanced renal cell carcinoma (RCC), according to study findings presented at the European Society for Medical Oncology 2018 Congress in Munich, Germany.11/08/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Germany Health | Kidney Cancer | Politics | Renal Cell Carcinoma | Study | Urology & Nephrology